Month: November 2022

Newest Hire Strengthens Infillion’s Leadership Team as Company Continues to Rapidly Grow Its Business

LOS ANGELES – November 1, 2022 – (Newswire.com)

Infillion, an advertising platform built for the connected future, today announced the appointment of Margaret Chu as chief financial officer. This announcement comes after her work as an executive advisor at Infillion. As an experienced business leader across media, advertising and technology, Margaret will work closely with Infillion’s management team to advance the company’s growth strategy as it continues to expand its presence as a leader in media technology.

“Infillion is growing rapidly, and having a savvy business partner like Margaret, who knows how to drive organic and inorganic growth, will help us move into the next phase of success,” said Rob Emrich, Founder and Executive Chair, Infillion. “Margaret has a proven track record of building successful companies and has been instrumental in corporate development activity in the media industry for a number of years. We are looking forward to putting her vast expertise to work at Infillion.”

Based in New York City, Margaret brings more than 20 years of relevant experience. Prior to joining Infillion’s executive leadership team, she served as chief financial officer at Vox Media where she delivered unprecedented financial results. Margaret has held previous executive roles at Horizon Media and RSE Ventures where she led legal, corporate strategy, investments, mergers and acquisitions and financial operations. Margaret has also served as board director or observer at Momofuku, Milk Bar, Legendary Entertainment and TransDigm Group. She is a proud alumna of Dartmouth College and Harvard Business School, where she earned her MBA.

“Infillion is an outstanding company in a sea of media technology solutions. Infillion’s impressive performance to-date and strong balance sheet positions the company to be nimble in how we choose to grow,” said Margaret Chu, CFO, Infillion. “I look forward to working with Infillion’s management team to develop dynamic tech that humanizes digital experiences for consumers and delivers great results for brands and agencies.”

Margaret officially joined the team in September, on the heels of welcoming Christa Carone as President of Infillion Media and Laurel Rossi as Chief Marketing Officer, well-known industry leaders in the media and advertising industries. 

For more information on Infillion and its people, visit https://infillion.com/. 

About Infillion

Infillion is an advertising platform built for the connected future and Web3. Working across more than 1,200 brands, such as Amazon, Microsoft, Bank of America and T-Mobile and all major agencies and holding companies, Infillion provides full-service media solutions that respect and prioritize consumers’ time, attention and privacy. Infillion’s CTV advertising solutions offer unparalleled scale with premium inventory, unconstrained by walled gardens. The company is devoted to innovating advertising by improving the user experience and providing advertisers and publishers with engaging, interactive ad formats that captivate consumers while respecting their time and providing an opportunity to opt-in. Infillion launched in February as the result of Gimbal’s acquisition of adtech CTV pioneer true[X] from Disney in late 2020. Both companies have been driving customer engagement with proprietary technology and first-party data since the beginning of marketing’s transformation to digital.

Contact Information:

Alyssa Kehoe

DiGennaro Communications

[email protected]

Press Release Service
by
Newswire.com

Original Source:

Infillion Appoints Margaret Chu as CFO

As published in the journal Food and Chemical Toxicology, the biopharmaceutical drug development firm’s sponsored research used co-cultured human, primary immune cells as a model to evaluate the ability of selected Cannabis constituents to decrease inflammation.

LAS VEGAS – November 1, 2022 – (Newswire.com)

Gb Sciences, Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and drug development company, has co-published a study in the journal Food and Chemical Toxicology that demonstrates the potential of selected cannabinoids and terpenes to reduce inflammation. Finding Cannabis compounds with anti-inflammatory properties may be useful in decreasing inflammation associated with a wide range of serious human disorders, and these Cannabis compounds potentially have more favorable side effect profiles than NSAIDs (Non-Steroidal Anti-Inflammatory Drugs), which currently lead the anti-inflammatory market based on sales. Largely because of the increasing prevalence of chronic and auto-immune inflammatory disorders, the market for anti-inflammatory therapies is expected to grow to $191.42 billion by 2027.

“We believe that this is the first demonstration of the anti-inflammatory potential of some very potent minor cannabinoids and terpenes derived from Cannabis,” said Dr. Andrea Small-Howard, President, Chief Science Officer, and Director of Gb Sciences. “The identification of cell type-specific immune modulating effects by different individual cannabinoids and terpenes was an important first step in designing our novel anti-inflammatory therapies. The results from our second study on the anti-inflammatory effects of proprietary mixtures of these ingredients will be published subsequently with our collaborators at Michigan State University and Chaminade University.”

Gb Sciences selected the specific Cannabis constituents for this study based on their prior activity within chemovar studies. To determine whether these cannabinoids and terpenes could reduce inflammation, Gb Sciences’ colleagues at Michigan State University tested the individual Cannabis constituents over a wide range of concentrations in human, primary immune cells in a co-culture system that mimics the complex interactions that regulate the human immune system. Three immune cell types were chosen as representatives within these native human immune cell mixtures based on their important roles in modulating the inflammatory cascade.

This study demonstrated that delta-9 tetrahydrocannabinol (THC) had the greatest effect on reducing inflammatory biomarkers and processes in all three immune cell types. Following THC, the greatest immune activity modulation was measured by cannabidivarin (CBDV), cannabigerol (CBG), cannabichromene (CBC), cannabinol (CBN), and lastly, cannabidiol (CBD) in decreasing order based on the number of statistically significant changes measured in inflammatory bioassays relative to the control. Some of these minor cannabinoids and the terpenes tested had very ‘selective’ anti-inflammatory effects, which targeted a single cell type and/or caused a change in only a single inflammatory bioassay.

This study entitled “Evaluation of the anti-inflammatory effects of selected cannabinoids and terpenes from Cannabis Sativa employing human primary leukocytes” was co-authored by Gb Sciences’ own President and Chief Science Officer, Andrea Small-Howard, and her collaborators Lance K. Blevins, Anthony P. Bach, Robert B. Crawford, Jiajun Zhou, Joseph E. Henriquez, Michael D. Rizzo, Sera Sermet, D.M. Isha Olive Khan, and Norbert Kaminski from Michigan State University (East Lansing, Michigan, USA) and Helen Turner from Chaminade University of Honolulu (Honolulu, Hawai’i, USA). The second part of this study measured the effects of proprietary mixtures of cannabinoids and terpenes on inflammation within this human, primary immune cell model, and this second study will be published next in collaboration with our colleagues at Michigan State University and Chaminade University.

To learn more about Gb Sciences, visit www.gbsciences.com.

About Gb Sciences and GbS Global Biopharma

Gb Sciences, Inc. is a plant-inspired, biopharmaceutical research and development company creating patented, disease-targeted formulations of cannabis- and other plant-inspired therapeutic mixtures for the prescription drug market through its Canadian subsidiary, GbS Global Biopharma, Inc. The ‘plant-inspired’ active ingredients in its therapeutic mixtures are synthetic homologues identical to the original plant compounds but produced under current Good Manufacturing Practices. Gb Sciences’ intellectual property portfolio contains six issued U.S. and three issued foreign patents, as well as 17 U.S. and 51 foreign patent-pending applications. In its drug development pipeline, Gb Sciences has five preclinical phase product development programs. Gb Sciences’ lead program for Parkinson’s disease is being prepared for a first-in-human clinical trial. Gb Sciences’ formulations for chronic pain, anxiety, and depression are currently in preclinical animal studies with researchers at the National Research Council of Canada. The company also received positive preclinical proof-of-concept data supporting its complex mixtures for the treatment of Cytokine Release Syndrome related to COVID-19, and its lead candidates will be optimized based on late-stage preclinical studies at Michigan State University. Gb Sciences’ productive research and development network includes distinguished universities, hospitals, and Contract Research Organizations. To learn more, visit www.gbsciences.com.

Forward-Looking Statements

This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as “expects”, “intends”, “plans”, “may”, “could”, “should”, “anticipates”, “likely”, “believes” and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company’s belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company’s control. It is possible that the Company’s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company’s business and financial and other results, are contained in the Company’s filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

Contact Information:

Madeleine Moench

[email protected]

Press Release Service
by
Newswire.com

Original Source:

Gb Sciences Co-Publishes Study Demonstrating Anti-Inflammatory Properties of Cannabis Ingredients

CARY, N.C. – November 1, 2022 – (Newswire.com)

InstantGMP, the originators of the all-in-one manufacturing and quality system, is proud to welcome a new contract development and manufacturing organization, Quality Chemical Laboratories (QCL), to its growing client base.

Quality Chemical Laboratories was founded in 1998 as a raw material testing laboratory and has continuously expanded capabilities and service offerings. For over 25 years, this leading CDMO has provided GMP-compliant formulation development and manufacturing services for the pharmaceutical industry. The company’s clients range from small start-up companies to some of the most prominent pharmaceutical corporations in the world.

As its client base continues to grow, Quality Chemical Laboratories recognized the importance of implementing a new software system to enhance its processes while gaining efficiency and maintaining GMP and FDA compliance.

QCL’s exhaustive search for a new software system led the company to the InstantGMP PRO system. While the software’s all-in-one capabilities impressed the QCL team, they required computer system validation to determine if the system:

• Meets FDA Part 11 compliance.
• Achieves its intended purpose by meeting user requirements.
• Is free from any installation or performance issues that could negatively impact the integrity of the CDMO’s production cycles, raw materials or finished pharmaceutical products.

To ensure that the InstantGMP PRO system was validated, Quality Chemical Laboratories conducted an extensive software vendor audit. During the software vendor auditing process, QCL reviewed every piece of the software’s validation documentation and standard operating procedures (SOPs) via a virtual session with InstantGMP to confirm that InstantGMP PRO:

• Is properly validated.
• Vendor documentation can be appropriately leveraged to save QCL significant time and resources.
• Functions accordingly and accurately.
• Aligns with the information defined in the provided user requirement documentation.

After QCL reviewed all the respective documentation and asked any pertinent questions, it created and supplied a detailed audit report that identified topics that required further discussion and some minor issues that needed to be resolved. At the conclusion of the audit process, InstantGMP successfully satisfied Quality Chemical Laboratories’ requirements.

Not only did this process lead to a successful relationship, but it also provided the QCL team a better understanding of the software’s full capabilities. Additionally, the audit process offered InstantGMP an opportunity to address previously unidentified issues and further enhance the software with new features that best meet manufacturers’ needs.

InstantGMP is excited to provide Quality Chemical Laboratories with a validated all-in-one software system that truly meets its needs for improved processes and assured compliance. InstantGMP wishes them continued success in the contract formulation development and manufacturing industry and thanks them for helping InstantGMP enhance their software during the audit process.

To learn more about InstantGMP PRO‘s new features and software auditing processes for GMP manufacturers, contact us to schedule a demonstration.

Contact Information:

Robert Pochadt

Director of Sales

[email protected]

215-975-9660

Jeremy Hall

Technical Sales Manager

[email protected]

757-759-4500

Related Files
InstantGMP PRO for FDA Requlated Industries 4.22.pdf

Press Release Service
by
Newswire.com

Original Source:

New CDMO Client, Quality Chemical Laboratories, Benefits From InstantGMP’s All-in-One Quality & Manufacturing System and Software Auditing for GMP Manufacturers